Vaccines

Mia Moore, PhD, presents findings showing 74% reduction in hospitalizations and key insights into primary vaccination and booster impact on population immunity in Washington and Oregon.

New pharmacokinetic data, shared by Moupali Das, MD, MPH, reveal long-lasting plasma concentrations, surpassing twice-yearly subcutaneous formulation for HIV prevention

Nilu Goonetilleke, LLBHons, BScHons, PhD, presents findings showing the bivalent HIVconsvX vaccine targets both Mosaic-1 and Mosaic-2, resulting in broader immune responses.

Nilu Goonetilleke, LLBHons, BScHons, presents findings from the phase 1 study, showing a 50% reduction in T cell response with age, while 85% of participants demonstrated strong immune responses.

Stacy Lindborg, PhD, highlights the vaccine’s immune response, safety, and global distribution potential.

Sean Tucker, PhD, highlights effective immune response and mucosal immunity, paving the way for broader applications in viral disease prevention.

Phase 1b trial data demonstrated immune response, with 85% reduction in viral shedding and robust mucosal immunity in elderly adults.

The phase 1/2a trial of BioNTech's BNT165e vaccine, involving nearly 180 participants, faces delays as global malaria control efforts struggle with funding and political uncertainties.

Kate Broderick, PhD, discusses the advancements in RNA-based vaccines for targeting flu, cancer, malaria, HIV, and more.

Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.

The interim results demonstrated a slightly better vaccine effectiveness in individuals who are immunocompetent vs immunocompromised individuals.

The most recent CDC report accounts for 33 million flu illnesses, 430,000 hospitalizations, and 19,000 deaths this flu season, with Influenza A(H1N1) and A(H3N2) as the primary strains.

The World Health Organization (WHO) reports on the vaccine uptake in that region, and the Global Polio Eradication Initiative reports that some countries recording new cases.

A new study published in JAMA Network Open points out that immunization also occurred in individuals who did not receive routine prenatal or infant vaccines.

Confirmed measles cases in Texas have risen from 24 to 58 in just six days, with 13 hospitalizations reported.

The company's trivalent vaccine (mRNA-1403) was being studied in a phase 3 trial.

In a statement, the official, Ralph Abraham, MD, along with the state’s deputy surgeon general, wrote that because of “COVID missteps” they will no longer encourage vaccination to people.

In the Phase 3 trial, GSK's vaccine met all 11 primary endpoints, providing expanded options for preventing invasive meningococcal disease in individuals aged 10-25 years.

The approval is based on positive phase 3 clinical trial results, offering an effective option for travelers and others at risk of chikungunya, the mosquito-borne illness.

Heather Platt, MD, discusses Merck’s latest achievement with Capvaxive and its potential to significantly reduce invasive pneumococcal disease and pneumonia in high-risk adult populations across Europe.

Robert Walker, MD discussed the company's application for full licensure and the importance of vaccination.

Vaccines and treatments are up for approval in early to mid-2025, including a chikungunya vaccine, a meningococcal vaccine, a monoclonal antibody for RSV, and more.

In a small trial, the Hecolin hepatitis E vaccine demonstrated further utility outside of previous study parameters.

The Phase 1 clinical trial for ARCT-2304, a self-amplifying mRNA vaccine, seeks to address pandemic influenza risk as H5N1 cases increase.

As politics increasingly intersects with science, infectious disease clinicians are called to take on advocacy roles. By engaging with their communities, clinicians can dispel misconceptions, highlight the importance of federal health institutions, and emphasize their role in safeguarding public health and advancing medical progress.